Last reviewed · How we verify
Intrarectal NRL001 Gel
Intrarectal NRL001 Gel is a Small molecule drug developed by Norgine. It is currently in Phase 1 development. Also known as: methoxamine gel 1.0%.
At a glance
| Generic name | Intrarectal NRL001 Gel |
|---|---|
| Also known as | methoxamine gel 1.0% |
| Sponsor | Norgine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intrarectal NRL001 Gel CI brief — competitive landscape report
- Intrarectal NRL001 Gel updates RSS · CI watch RSS
- Norgine portfolio CI
Frequently asked questions about Intrarectal NRL001 Gel
What is Intrarectal NRL001 Gel?
Intrarectal NRL001 Gel is a Small molecule drug developed by Norgine.
Who makes Intrarectal NRL001 Gel?
Intrarectal NRL001 Gel is developed by Norgine (see full Norgine pipeline at /company/norgine).
Is Intrarectal NRL001 Gel also known as anything else?
Intrarectal NRL001 Gel is also known as methoxamine gel 1.0%.
What development phase is Intrarectal NRL001 Gel in?
Intrarectal NRL001 Gel is in Phase 1.
Related
- Manufacturer: Norgine — full pipeline
- Also known as: methoxamine gel 1.0%
- Compare: Intrarectal NRL001 Gel vs similar drugs
- Pricing: Intrarectal NRL001 Gel cost, discount & access